EMI (Encore Medical) Tax Provision: $0.00 Mil (TTM As of Dec. 2025)


What is Encore Medical Tax Provision?

Encore Medical EMI Tax Provision is $0.00 Mil as of Dec. 2025.

Encore Medical's tax provision for the three months ended in Dec. 2025 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil.

Encore Medical Tax Provision Historical Data

* Premium members only.

The historical data trend for Encore Medical's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Encore Medical Tax Provision Chart

Encore Medical Annual Data
Trend Dec23 Dec24 Dec25
Tax Provision
0.00 0.00 0.00

Encore Medical Quarterly Data
Dec23 Sep24 Dec24 Jun25 Sep25 Dec25
Tax Provision Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Encore Medical Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $0.00 Mil mean?
Encore Medical (EMI) has a Tax Provision of $0.00 Mil as of Dec. 2025. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Encore Medical and its competitors.
Is Encore Medical's Tax Provision too high?
Encore Medical's current Tax Provision is $0.00 Mil.
How does Encore Medical's Tax Provision compare to ?
Encore Medical's Tax Provision of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Medical Devices & Instruments company?
A good Tax Provision depends on the Medical Devices & Instruments industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Encore Medical and its competitors. Encore Medical's current Tax Provision is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Encore Medical stock overvalued right now?
Encore Medical (EMI) has a current Tax Provision of $0.00 Mil. The current Tax Provision is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Encore Medical (EMI), the current Tax Provision is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Encore Medical Business Description

Comparable Companies
Address 2975 Lone Oak Drive, Suite 140, Eagan, MN, USA, 55121
Encore Medical Inc develops, manufactures, and markets septal occlusion devices for the repair of certain cardiac defects. Its products have been implanted in approximately 35,000 patients outside the United States. Its closure device is designed to correct a cardiac defect, generally diagnosed in adulthood, known as a patent foramen ovale (PFO). The company also currently market and sell septal occlusion devices for the transcatheter closure of atrial septal defects (ASD).